Two stem-cell transplants better than one in neuroblastoma
The trial including Australian patients 'has changed current practice', experts say
Two autologous stem-cell transplants provide better event-free survival in patients with high-risk neuroblastoma, compared with a single stem-cell transplant, a clinical trial shows.
Researchers from 142 Children’s Oncology Group centres in five countries, including Australia and New Zealand, investigated whether intensifying consolidation treatment with tandem transplant (two transplants, 6-10 weeks apart) could improve event-free survival compared with a single transplant.
